XC221 / RSV Therap - LARVOL DELTA

A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections (clinicaltrials.gov) - P3 | N=260 | Completed | Sponsor: Valenta Pharm JSC | Recruiting ➔ Completed | Trial completion date: Dec 2024 ➔ May 2023 | Trial primary completion date: Dec 2024 ➔ Feb 2023

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases

A Study to Assess the Efficacy and Safety of XC221 in Patients With Mild COVID-19 (clinicaltrials.gov) - P3 | N=274 | Completed | Sponsor: RSV Therapeutics LLC | Recruiting ➔ Completed | Trial primary completion date: Dec 2022 ➔ Aug 2022

Trial completion • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Study of the Effect of Food Intake on the Bioavailability of XC221 100 mg Tablets (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Valenta Pharm JSC | Recruiting ➔ Completed | N=46 ➔ 24

Enrollment change • Trial completion

A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections (clinicaltrials.gov) - P3 | N=260 | Recruiting | Sponsor: Valenta Pharm JSC

New P3 trial • Infectious Disease • Respiratory Diseases

A Study to Assess the Efficacy and Safety of XC221 in Patients With Mild COVID-19 (clinicaltrials.gov) - P3 | N=274 | Recruiting | Sponsor: RSV Therapeutics LLC | Trial completion date: Dec 2021 ➔ Dec 2022 | Trial primary completion date: Dec 2021 ➔ Dec 2022

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections (clinicaltrials.gov) - P2 | N=255 | Completed | Sponsor: Valenta Pharm JSC | Recruiting ➔ Completed

Trial completion • Infectious Disease • Respiratory Diseases

Study of the Effect of Food Intake on the Bioavailability of XC221 100 mg Tablets (clinicaltrials.gov) - P1 | N=46 | Recruiting | Sponsor: Valenta Pharm JSC

New P1 trial

A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections (clinicaltrials.gov) - P2; N=255; Recruiting; Sponsor: Valenta Pharm JSC; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Respiratory Diseases

A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections (clinicaltrials.gov) - P2; N=255; Not yet recruiting; Sponsor: Valenta Pharm JSC

Clinical • New P2 trial • Infectious Disease • Respiratory Diseases

A Study to Assess the Efficacy and Safety of XC221 in Patients With Mild COVID-19 (clinicaltrials.gov) - P3; N=274; Recruiting; Sponsor: RSV Therapeutics LLC; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study to Assess the Efficacy and Safety of XC221 in Patients With Mild COVID-19 (clinicaltrials.gov) - P3; N=274; Not yet recruiting; Sponsor: RSV Therapeutics LLC

Clinical • New P3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI (clinicaltrials.gov) - P2; N=120; Completed; Sponsor: PHARMENTERPRISES LLC; Recruiting ➔ Completed

Clinical • Trial completion • Infectious Disease • Respiratory Diseases

A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19 (clinicaltrials.gov) - P3; N=118; Completed; Sponsor: RSV Therapeutics LLC; Recruiting ➔ Completed

Clinical • Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19 (clinicaltrials.gov) - P3; N=118; Recruiting; Sponsor: RSV Therapeutics LLC; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease

A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19 (clinicaltrials.gov) - P3; N=118; Not yet recruiting; Sponsor: RSV Therapeutics LLC

Clinical • New P3 trial • Infectious Disease • Novel Coronavirus Disease